Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.04%||170.12||0.7%||$1252.92m|
|MRK||Merck & Co., Inc.||0.33%||78.48||0.7%||$929.96m|
|BMY||Bristol-Myers Squibb Co.||-0.06%||64.84||1.0%||$719.56m|
|LLY||Eli Lilly & Co.||0.10%||196.40||1.1%||$573.53m|
|BTX||Brooklyn ImmunoTherapeutics, Inc.||-1.34%||21.40||12.8%||$252.76m|
|NVO||Novo Nordisk A/S||0.90%||79.82||0.1%||$72.84m|
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.